Correlation Between Veracyte and Lipella Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Veracyte and Lipella Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Veracyte and Lipella Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Veracyte and Lipella Pharmaceuticals Common, you can compare the effects of market volatilities on Veracyte and Lipella Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Veracyte with a short position of Lipella Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Veracyte and Lipella Pharmaceuticals.

Diversification Opportunities for Veracyte and Lipella Pharmaceuticals

0.54

Correlation Coefficient

Veracyte  Lipella Pharmaceuticals

Very weak diversification

The 3 months correlation between Veracyte and Lipella is 0.54. Overlapping area represents the amount of risk that can be diversified away by holding Veracyte and Lipella Pharmaceuticals Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lipella Pharmaceuticals and Veracyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Veracyte are associated (or correlated) with Lipella Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lipella Pharmaceuticals has no effect on the direction of Veracyte i.e., Veracyte and Lipella Pharmaceuticals go up and down completely randomly.

Pair Corralation between Veracyte and Lipella Pharmaceuticals

Given the investment horizon of 90 days Veracyte is expected to under-perform the Lipella Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Veracyte is 3.74 times less risky than Lipella Pharmaceuticals. The stock trades about -0.1 of its potential returns per unit of risk. The Lipella Pharmaceuticals Common is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  312.00  in Lipella Pharmaceuticals Common on December 29, 2024 and sell it today you would lose (53.00) from holding Lipella Pharmaceuticals Common or give up 16.99% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Veracyte  vs.  Lipella Pharmaceuticals Common

Veracyte

Risk-Adjusted Performance

Very Weak

Over the last 90 days Veracyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Lipella Pharmaceuticals

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Lipella Pharmaceuticals Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Lipella Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Veracyte and Lipella Pharmaceuticals

The main advantage of trading using opposite Veracyte and Lipella Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Veracyte position performs unexpectedly, Lipella Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will offset losses from the drop in Lipella Pharmaceuticals' long position.

The idea behind Veracyte and Lipella Pharmaceuticals Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.